GRI Bio (GRI) vs Mustang Bio (MBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Mustang Bio is the larger company by market cap ($2.7 million vs $2.4 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | MBIO |
|---|---|---|
| Share price | $1.12 | $0.3541 |
| Market cap | $2.45M | $2.69M |
| 1-day change | 0.00% | -4.30% |
| P/E ratio (TTM) | 0.05 | — |
| EPS (TTM) | $20.57 | $-0.51 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $-11.96M | $-1.92M |
| 52-week high | $64.12 | $1.43 |
| 52-week low | $1.09 | $0.35 |
| Distance from 52-week high | -98.25% | -75.24% |
| Analyst consensus | none | — |
| Avg. price target upside | +1551.79% | — |
| Average volume | 218.31K | 33.87K |
| Shares outstanding | 2.19M | 6.74M |
| Employees | 3 | 4 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Mustang Bio
MBIO stock →Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases in the United States. The company develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy which is in Phase I clinical trail for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-109, a combination MB-101 and MB-108 as a potential treatment for IL13Ra2+ relapsed or refractory glioblastoma and high-grade astrocytoma; MB-101, an IL13Ra2 CAR T cell program completd Phase I for glioblastoma; and MB-108 which is in Phase I for the treatment of herpes simplex virus-1 oncolytic virus C134.
Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees
GRI vs MBIO FAQ
Which is bigger, GRI Bio or Mustang Bio?
Mustang Bio (MBIO) is larger, with a market capitalization of $2.69M compared with $2.45M for GRI Bio (GRI).
Are GRI Bio and Mustang Bio in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.